Stephanie Carlin
Education
University of Toronto
Carlin attended the University of Toronto from 2006-2010 where she received a Bachelor of Science in Pharmacy.1)
Carlin recently finished an advanced practice pharmacy residency in thrombosis at Sunnybrook Health Sciences Centre through the University of Toronto.2)
Career and Affiliations
Hamilton Health Sciences
Carlin was a critical care pharmacist, and now a thrombosis pharmacist, at Hamilton Health Sciences.3)
Ontario COVID-19 Science Advisory Table
Carlin is a member of the Drugs & Biologics Clinical Practice Guidelines Working Group of the Ontario COVID-19 Science Advisory Table.4)
Research
Her research interests include optimization of antithrombotic use in clinical practice.
Funding
Carlin received funding from Sanofi for her advanced practice thrombosis residency program.5)
She also received joint payment from Bristol-Myers Squibb and Pfizer for an “educational presentation to health professionals on atrial fibrillation.6)
1)
Stephanie Carlin - Education. LinkedIn. Retrieved May 1, 2022, from https://www.linkedin.com/in/stephanie-carlin-6a471b13a/details/education/
2)
Carlin, S., Geerts, W., & Khosravani, H. (2021). The clot thickens—enhanced integration of stroke and thrombosis training. Journal of Thrombosis and Thrombolysis, 53(1), 17–19. https://doi.org/10.1007/s11239-021-02502-7
3)
Stephanie Carlin · Pharmacist · Hamilton Health Sciences. OpenGovCA. Retrieved May 1, 2022, from https://web.archive.org/web/20220501183726/https://opengovca.com/ontario-employee/stephanie-carlin
4)
About Us. Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/
5)
Carlin, S. (2021, February 10). Declaration of Interest. Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220501184628/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Stephanie-Carlin-1.pdf
6)
Carlin, S., & Eikelboom, J. (2022). Advances in anticoagulation: patients with bioprosthetic heart valves. Cardiovascular Research, 118(3), e26–e28. https://doi.org/10.1093/cvr/cvab360